|
gptkbp:instanceOf
|
gptkb:anticoagulant
direct thrombin inhibitor
|
|
gptkbp:antidote
|
gptkb:idarucizumab
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
2008
|
|
gptkbp:ATCCode
|
B01AE07
|
|
gptkbp:bioavailability
|
3-7%
|
|
gptkbp:brand
|
gptkb:Pradaxa
|
|
gptkbp:CASNumber
|
211915-06-9
|
|
gptkbp:contraindication
|
severe renal impairment
active pathological bleeding
|
|
gptkbp:developedBy
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:drugClass
|
NOAC (novel oral anticoagulant)
|
|
gptkbp:eliminationHalfLife
|
12-17 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:hasMolecularFormula
|
C34H41N7O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Dabigatran etexilate
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits thrombin (factor IIa)
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:molecularWeight
|
627.74 g/mol
|
|
gptkbp:patentExpired
|
2023 (US)
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:prodrugOf
|
gptkb:dabigatran
|
|
gptkbp:proteinBinding
|
35%
|
|
gptkbp:riskFactor
|
increased bleeding with P-gp inhibitors
not recommended in mechanical heart valves
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
bleeding
gastrointestinal upset
|
|
gptkbp:storage
|
store at room temperature, protect from moisture
|
|
gptkbp:usedFor
|
prevention of stroke in atrial fibrillation
treatment of deep vein thrombosis
treatment of pulmonary embolism
|
|
gptkbp:bfsParent
|
gptkb:DB09054
|
|
gptkbp:bfsLayer
|
6
|